Active Surveillance Selection and Durability in Men with NCCN Intermediate-Risk, Localized Prostate Cancer Who Had Genetic Testing

Chelsea R. Kasten; Lauren Lenz; Wyatt Clegg; Diana Iliev; Howard J. Korman; Todd M. Morgan; Jason M. Hafro; Alexander P. DeHaan; Ronald F. Tutrone, Jr.; Paul M. Yonover; Jeff Jasper; Alexander Gutin; Robert Finch; Thomas P. Slavin, Jr.; Todd Cohen

1. Myriad Genetics, Inc. Salt Lake City, UT, USA; 2. Comprehensive Urology Royal Oak, MI, USA; 3. University of Michigan, Ann Arbor, MI, USA; 4. Michigan Institute of Urology, Troy, MI, USA; 5. Urology Consultants, Wyoming, MI, USA; 6. Chesapeake Urology, Towson, MD, USA; 7. UroPartners, LLC, Chicago, IL, USA

Background

- High-quality evidence and guidelines support active surveillance (AS) in intermediate-risk prostate cancer with favorable clinical variables.1,2
- Genomic testing can add valuable information to standard clinical risk factors, allowing for more accurate identification of AS candidates.
- Objective: To describe initial AS selection and 3-year durability in men with NCCN intermediate-risk prostate cancer who received genetic testing.

Results

Table 1: Patient Demographics

<table>
<thead>
<tr>
<th>Statistic</th>
<th>AS Selection Analysis Set</th>
<th>AS Durability Analysis Set</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (%) or Median (IQR)</td>
<td>N (%) or Median (IQR)</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>3208</td>
<td>960</td>
</tr>
<tr>
<td>Initial AS Selection</td>
<td>975 (30.4%)</td>
<td>960 (100%)</td>
</tr>
<tr>
<td>Age</td>
<td>67 (61, 72)</td>
<td>68 (62, 73)</td>
</tr>
<tr>
<td>Gleason Score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3+3</td>
<td>331 (10.3%)</td>
<td>183 (19.1%)</td>
</tr>
<tr>
<td>3+4</td>
<td>2219 (69.2%)</td>
<td>699 (72.8%)</td>
</tr>
<tr>
<td>4+3</td>
<td>658 (20.5%)</td>
<td>78 (8.1%)</td>
</tr>
<tr>
<td>CCP</td>
<td>-0.6 (-1.0, -0.1)</td>
<td>-0.8 (-1.2, -0.3)</td>
</tr>
<tr>
<td>CAPRA</td>
<td>3 (2, 4)</td>
<td>3 (2, 3)</td>
</tr>
<tr>
<td>CCR</td>
<td>0.933 (0.495, 1.446)</td>
<td>0.657 (0.324, 1.056)</td>
</tr>
<tr>
<td>Below AS Threshold</td>
<td>1470 (45.8%)</td>
<td>605 (63.0%)</td>
</tr>
</tbody>
</table>

Methods

Genetic Testing

- The clinical cell-cycle risk (CCR) score combines the University of California, San Francisco’s Cancer of the Prostate Risk Assessment (CAPRA) and the cell cycle progression molecular score to accurately assess prostate cancer aggressiveness.
- Recommends patients for AS based on a validated threshold. e.g., 3, 4

AS Selection

- Defined as no switch to definitive treatment (DT) within 6 months from time of initial diagnosis.
- Univariable and multivariable logistic regression models were used to evaluate initial treatment decisions.

AS Durability

- Defined as time from diagnosis to first treatment for patients who initially chose AS.
- Cox proportional hazard models and Kaplan-Meier methods were used to evaluate AS durability.

Figure 1: Study Design

![Study Design Diagram]

Figure 2: Initial AS Selection

![Initial AS Selection Chart]

- All genetically tested patients (N = 3208)
- AS recommended: N = 1470, 45.8%
- DT recommended: N = 1738, 54.2%

- Of patients recommended AS by genetic testing, 41.8% selected AS.
- Of patients recommended DT by genetic testing, only 20.7% selected AS.

Figure 3: 3-Year AS Durability in Patients who Initially Selected AS

![3-Year AS Durability Chart]

- For patients recommended AS by genetic testing, AS durability was 52.4% at 3 years.
- For patients recommended DT by genetic testing, AS durability was 34.7% at 3 years.

Discussion

- The observed 41.8% AS selection rate in this study exceeds previously observed rates.
- Without access to genomic information, 7.5% of intermediate-risk patients chose AS over the same time period.3
- In the AQUA Registry, 10.4% of intermediate-risk patients chose AS in 2014 and 20.4% chose AS in 2019.6
- The current study largely predated guideline changes noting the utility of AS in favorable-intermediate risk men, indicating that AS rates may continue to increase.7, 8
- Conclusion: The personalized risk information offered by genetic testing can help identify AS candidates and was predictive of AS durability, thereby informing treatment decisions and improving clinical outcomes.

References

1. NCCN Guidelines. Prostate Cancer V 1.2023
2. Eastham et al. 2022 J Urol
4. Tward et al. 2022 Int J Radiat Oncol Biol Phys
5. Botejue et al. 2019 J Urol
7. Mohler et al. 2019 Natl Comprr Canc Netw
8. Sanda et al. 2018 2018